Vol. 5 No. 6 (2026), Articles
Vol. 5 No. 6 (2026)

POLIKISTIK TUXUMDONLAR SINDROMI: REPRODUKTIV SALOMATLIKKA TA’SIRI, METABOLIK BUZILISHLAR VA INDIVIDUAL DAVOLASH YONDASHUVLARI

Articles
Published 2026-10-25
Bekmirzayeva Mushtariy Komiljon qizi
Toshkent Xalqaro Kimyo Universiteti Namangan filiali(KIUT) Davolash ishi fakultetining 3-bosqich talabasi
Kamalova Gulnora Gulyamovna
Toshkent Kimyo Xalqaro Universiteti Namangan filiali(KIUT) v.b dotsent, PhD
PDF

Keywords

polikistik tuxumdonlar sindromi, reproduktiv salomatlik, insulin rezistentligi, giperandrogenizm, anovulyatsiya, bepushtlik, metabolik sindrom, glyukozaga tolerantlik, endometriy, individual davolash, ovulyatsiya induksiyasi, gormonal muvozanat, kardiometabolik xavf, turmush tarzini modifikatsiya qilish.

Abstract

Polikistik tuxumdonlar sindromi (PTKS) reproduktiv yoshdagi ayollarda uchraydigan, reproduktiv, endokrin va metabolik tizimlar faoliyatidagi o‘zaro bog‘liq o‘zgarishlar bilan tavsiflanadigan ko‘p omilli klinik sindrom hisoblanadi. Uning asosiy klinik belgilari hayz siklining buzilishi, ovulyatsiyaning muntazam sodir bo‘lmasligi, giperandrogenizm, homiladorlikka erishishdagi qiyinchiliklar va ayrim bemorlarda insulin rezistentligi bilan bog‘liq metabolik o‘zgarishlardan iborat. Sindromning klinik ko‘rinishi turlicha bo‘lib, kasallikning namoyon bo‘lish darajasi bemorning yoshi, gormonal holati, tana vazni, irsiy moyilligi va reproduktiv maqsadlariga qarab farqlanadi. Shu sababli PTKSni tashxislash va davolashda kompleks, individual yondashuvdan foydalanish muhim ahamiyatga ega. Jahon sog‘liqni saqlash tashkiloti ma’lumotlariga ko‘ra, ushbu sindrom reproduktiv yoshdagi ayollarning taxminan 10–13 foizida uchraydi, biroq ko‘plab holatlarda tashxis o‘z vaqtida qo‘yilmaydi. Mazkur maqolaning maqsadi polikistik tuxumdonlar sindromining reproduktiv salomatlikka ta’sirini, metabolik buzilishlar bilan patogenetik bog‘liqligini va zamonaviy individual davolash yondashuvlarini ilmiy adabiyotlar asosida tahlil qilishdan iborat. Tadqiqot metodologiyasi sifatida xalqaro klinik tavsiyalar, konsensus hujjatlari, tizimli sharhlar va sindromning diagnostik mezonlariga bag‘ishlangan ilmiy manbalarning qiyosiy tahlili qo‘llanildi. Tahlil natijalari PTKSni faqat tuxumdon morfologiyasidagi o‘zgarishlar bilan cheklab bo‘lmasligini, uning reproduktiv va metabolik oqibatlarini birgalikda baholash zarurligini ko‘rsatadi. Insulin rezistentligi va giperinsulinemiya ayrim bemorlarda androgenlar ishlab chiqarilishining kuchayishiga, follikullar rivojlanishining buzilishiga va ovulyator disfunksiyaning chuqurlashishiga yordam berishi mumkin. Shu bilan birga, barcha bemorlarda metabolik buzilishlar bir xil darajada namoyon bo‘lmaydi. Davolash strategiyasini tanlashda hayz siklini tartibga solish, endometriyni himoya qilish, giperandrogenizm belgilarini kamaytirish, metabolik xavflarni nazorat qilish va zarur hollarda ovulyatsiyani induksiya qilish kabi maqsadlar hisobga olinishi lozim. Xulosa qilib aytganda, PTKSni samarali boshqarish uchun turmush tarzini sog‘lomlashtirish, metabolik ko‘rsatkichlarni muntazam baholash va bemorning reproduktiv rejasiga mos davolash usullarini birlashtirgan kompleks yondashuv zarur.                      

PDF

References

1. World Health Organization. Polycystic ovary syndrome. Geneva: World Health Organization; 2026. Elektron axborot materiali. URL: https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome.

2. Teede H.J., Tay C.T., Laven J.J.E. va boshq. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2447–2469. Oxford University Press. DOI: 10.1210/clinem/dgad463.

3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004;19(1):41–47. Oxford University Press. DOI: 10.1093/humrep/deh098.

4. Azziz R., Carmina E., Chen Z. va boshq. Polycystic ovary syndrome. Nature Reviews Disease Primers. 2016;2:16057. Springer Nature. DOI: 10.1038/nrdp.2016.57.

5. Escobar-Morreale H.F. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology. 2018;14:270–284. Springer Nature. DOI: 10.1038/nrendo.2018.24.

6. Teede H.J., Misso M.L., Costello M.F. va boshq. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction. 2018;33(9):1602–1618. Oxford University Press. DOI: 10.1093/humrep/dey256.

7. Legro R.S., Arslanian S.A., Ehrmann D.A. va boshq. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2013;98(12):4565–4592. Endocrine Society / Oxford University Press. DOI: 10.1210/jc.2013-2350.

8. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 1997;18(6):774–800. Oxford University Press. DOI: 10.1210/edrv.18.6.0318.

9. Moran L.J., Misso M.L., Wild R.A., Norman R.J. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update. 2010;16(4):347–363. Oxford University Press. DOI: 10.1093/humupd/dmq001.

10. Tuxumdonlar polikistozi sindromi tasnifi va patogeneziga zamonaviy qarashlar. O‘zbek tilidagi elektron o‘quv-ilmiy material. ZiyoNET elektron kutubxonasi.URL:https://api.ziyonet.uz/uploads/books/10003764/NDTEUFF80jHtItY.pdf.